TSHA

3.7001.86%
LS

Laura Sepp-Lorenzino

Independent Director

Dr. Laura Sepp-Lorenzino, Ph.D., is Member of Scientific Advisory Board of Aerska, Inc. from September 2026. She also serves on the scientific advisory board of Inverna Therapeutics. Dr. Sepp-Lorenzino is Member of Scientific Advisory Board of Mana Bio. Dr. Sepp-Lorenzino serves as Director at Lexeo Therapeutics, Inc. since April 28, 2026. She was Director of Sail Biomedicines, Inc. until 2025. She is Director of LARONDE, Inc. from 2025. Dr. Sepp-Lorenzino is Independent Director of Asklepios BioPharmaceutical, Inc. from April 4, 2025. Dr. Sepp-Lorenzino serves as Independent Director at Taysha Gene Therapies, Inc. since November 23, 2020. She is Director of Alliance for Regenerative Medicine. She had been Executive Vice President and Chief Scientific Officer of Intellia Therapeutics, Inc. since May 2019 until January 13, 2025 and remain with the company as Special Advisor until December 31, 2025. She joined Intellia from Vertex Pharmaceuticals, Inc., where she was vice president, head of Nucleic Acid Therapies, Research Leadership and member of the External Innovation team. At Vertex, she focused on developing an integrated nucleic acid therapies strategy through internal programs and key research collaborators She has decades of leadership and research and development experience and joined Intellia to head its drug research organization. Prior to working at Vertex, Dr. Sepp-Lorenzino was vice president, entrepreneur-in-residence and head of the Hepatic Infectious Disease Strategic Therapeutic Area at Alnylam Pharmaceuticals, Incorporated from 2014 to September 2017. During her time at Alnylam, she developed and implemented the company’s hepatic infectious disease strategy, championed extra-hepatic oligonucleotide delivery, helped secure long-term research partnerships and built a strong pipeline of RNA interference (RNAi) drug candidates. Dr. Sepp-Lorenzino joined Alnylam in 2014. Dr. Sepp-Lorenzino serves as Member of Scientific Advisory Board at Thermo Fisher Scientific Inc. since October 2018. Before joining Alnylam, Dr. Sepp-Lorenzino spent at Merck & Co. and served as Executive Director and Department Head, RNA Therapeutics Discovery Biology. In this role, she was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of pre-clinical candidates and development of siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Prior to RNAi, she worked in oncology drug discovery and development, having led the Cancer Research Department at Merck West Point and having been an Assistant Lab Member at Memorial Sloan-Kettering Cancer Center. She holds professional affiliations with key scientific organizations, including the Oligonucleotide Therapeutics Society, the American Society for Gene and Cell Therapy and the European Society of Gene and Cell Therapy, as well as a number of professional societies. Dr. Sepp-Lorenzino has given more than 30 lectures since 2011 and published more than 80 journal articles. As a leading mind in the field, she has been a peer reviewer for more than 11 scientific journals, including Nature Biotechnology. Dr. Sepp-Lorenzino received her Professional Degree in Biochemistry from the University of Buenos Aires and her M.S. and Ph.D. in Biochemistry from New York University.

Positions